Myriad Genetics Inc. (MYGN) is Trading Lower on Unusual Volume for January 18

Equities Staff |

Myriad Genetics Inc. (MYGN) experienced unusually high volume on Jan. 18, as the stock lost 5.24% to a closing price of $40.17. The stock saw 2.13 million shares trade hands over the course of the day on 9,929 trades. Given that the stock’s average daily volume over the last month has been 796,455 shares a day, this represents a pretty substantial spike over the norm.

Myriad Genetics Inc. has a P/B ratio of 4.08. It also has a P/E ratio of 32.4. The stock has traded between $46.24 and $30.30 over the last 52-weeks, its 50-day SMA is now $43.27, and its 200-day SMA $37.52.

Myriad Genetics Inc is a molecular diagnostic company. It develops and markets novel predictive medicine, personalized medicine and prognostic medicine tests. It also provides physicians with information to solve unmet medical needs.

Headquartered in Salt Lake City, UT, Myriad Genetics Inc. has 2,038 employees and is currently under the leadership of CEO Mark Christopher Capone.

For a complete fundamental analysis analysis of Myriad Genetics Inc., check out’s Stock Valuation Analysis report for MYGN. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Pressure Biosciences Inc

Pressure BioSciences Inc is a biological life sciences research company. It is engaged in the development and commercialization of a platform technology called pressure cycling technology.

Private Markets

CF0005, LLC dba Mesa-Marshall #1-2

MESA Resources, Inc. ("MESA") is sponsoring the development of the oil & gas well completion project "Mesa-Marshall #1-2". MESA, founded in 1992, is engaged in the acquisition, exploration and development…


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…